Pegapamodutide - Transition Therapeutics
Alternative Names: LM-008 - LeaderMed; LY-2944876; OPK 88003; Oxyntomodulin analog - Eli Lilly and Company; TT-401Latest Information Update: 09 Oct 2024
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; OPKO Health; Transition Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Oct 2024 LeaderMed Group plans a phase-III trial for Type 2 diabetes mellitus and Obesity in Indonesia (SC),
- 30 Sep 2024 LeaderMed Group and Combiphar forms joint venture for develop and commercialize pegapamodutide in Indonesia
- 14 Sep 2021 LeaderMed Group and OPKO Health enters into joint venture for develop and commercialize pegapamodutide in Asia, China, Hong Kong, Taiwan and Macau